Live price temporarily unavailable.
Shattuck Labs (STTK) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $9.89M | $9.93M | $30.0M | $652.0K | $1.66M | $5.72M | $1.00M |
| Growth (year over year) | — | +0.5% | +202.2% | −97.8% | +154.1% | +245.3% | −82.5% |
| Operating income | −$25.1M | −$36.9M | −$45.3M | −$103.3M | −$92.0M | −$80.6M | −$51.5M |
| Operating margin | −253.5% | −371.8% | −150.8% | −15848.0% | −5549.6% | −1408.3% | −5150.8% |
| Net income | −$24.0M | −$36.6M | −$45.0M | −$101.9M | −$87.3M | −$75.4M | −$48.8M |
| Net margin | −242.6% | −368.5% | −149.8% | −15635.7% | −5268.4% | −1318.1% | −4880.9% |
| EPS (diluted) | −$3.17 | −$2.36 | −$1.07 | −$2.41 | −$2.05 | −$1.49 | −$0.70 |
| Balance sheet | |||||||
| Cash and equivalents | $7.01M | $157.9M | $92.3M | $47.4M | $125.6M | $57.4M | $54.2M |
| Total assets | $45.0M | $349.0M | $298.6M | $205.3M | $159.6M | $91.0M | $91.0M |
| Total liabilities | $30.5M | $39.1M | $26.8M | $29.2M | $14.9M | $11.4M | $8.64M |
| Shareholders' equity | −$34.5M | $309.9M | $271.8M | $176.2M | $144.7M | $79.6M | $82.4M |
| Cash flow | |||||||
| Operating cash flow | −$21.0M | −$33.7M | −$57.1M | −$94.5M | −$81.2M | −$60.5M | −$39.9M |
| Capital expenditure | $470.0K | $727.0K | $7.93M | $11.6M | $407.0K | $59.0K | $71.0K |
| Free cash flow | −$21.4M | −$34.4M | −$65.0M | −$106.1M | −$81.6M | −$60.6M | −$40.0M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.00M | — | $0 | $0 | $1.00M | — | $0 | $0 |
| Growth (year over year) | +336.9% | — | −100.0% | −100.0% | −66.6% | — | — | — |
| Operating income | −$17.9M | — | −$14.4M | −$13.0M | −$10.7M | — | −$15.5M | −$16.2M |
| Operating margin | −597.9% | — | — | — | −1071.6% | — | — | — |
| Net income | −$16.7M | — | −$13.7M | −$12.5M | −$10.1M | — | −$14.8M | −$15.2M |
| Net margin | −556.4% | — | — | — | −1005.6% | — | — | — |
| EPS (diluted) | −$0.33 | — | −$0.27 | −$0.24 | −$0.14 | — | −$0.13 | −$0.12 |
| Balance sheet | ||||||||
| Cash and equivalents | $43.8M | $57.4M | $60.9M | $50.5M | $42.5M | $54.2M | $90.4M | $63.3M |
| Total assets | $111.7M | $91.0M | $77.2M | $64.4M | $100.3M | $91.0M | $102.1M | $220.7M |
| Total liabilities | $15.1M | $11.4M | $9.58M | $7.35M | $7.09M | $8.64M | $6.29M | $9.53M |
| Shareholders' equity | $96.6M | $79.6M | $67.6M | $57.0M | $93.2M | $82.4M | $95.8M | $211.1M |
| Cash flow | ||||||||
| Operating cash flow | −$16.1M | — | −$12.0M | −$10.4M | −$8.93M | — | −$13.4M | −$10.2M |
| Capital expenditure | $42.0K | — | — | — | $71.0K | — | — | — |
| Free cash flow | −$16.1M | — | — | — | −$9.00M | — | — | — |
From Shattuck Labs's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning Shattuck Labs in our feed yet.